Irinotecan dysarthria
WebApr 1, 2024 · Irinotecan-induced dysarthria has been reported in the literature, but the underlying mechanism of this neurotoxicity remains unclear. Here, we present a 35-year-old female with metastatic colon cancer who experienced dysarthria during irinotecan infusion. WebJan 18, 2012 · In conclusion, selective irinotecan-induced dysarthria is an unusual and impressive entity, which can occur within minutes of irinotecan infusion. It is potentially related to a relative cholinergic oversensitivity of neurons in the area of the nucleus of the hypoglossal nerve. Though atropine can decrease cholinergic symptoms, it has not been ...
Irinotecan dysarthria
Did you know?
WebNational Center for Biotechnology Information WebNational Center for Biotechnology Information
WebJan 19, 2013 · Irinotecan. A 34-year-old man with metastatic sarcoma and a 63-year-old woman with disseminated adenocarcinoma developed CNS toxicity with dysarthria during treatment with irinotecan. The woman also experienced an acute cholinergic syndrome. The man, who had experienced partial remission of his sarcoma following antineoplastic … WebIrinotecan-associated dysarthria: A single institution case series with management implications in patients with gastrointestinal malignancies Article Mar 2024 David Bing Zhen Rachel L McDevitt...
WebJul 23, 2024 · Irinotecan is a topoisomerase-I inhibitor that is commonly used in combination with other chemotherapy agents for gastrointestinal malignancies. It has … WebJul 1, 2008 · DISCUSSION. The mechanism by which irinotecan and its active metabolite SN-38 binds and inhibits anticholinesterase has been well described; 4, 5 however, the mechanism by which CNS toxicity occurs after irinotecan infusion is unclear. We are aware of four cases of irinotecaninduced dysarthria reported in the literature, 9 – 12 but to the …
WebJun 28, 2024 · Dysarthria, a state of difficult or unclear articulation of speech, has been reported as a rare side effect of irinotecan through multiple case reports and case series, but with limited published data aimed at understanding the underlying mechanism and effective management strategies.
WebSep 19, 2001 · Irinotecan (CPT-11) is a semisynthetic analogue of camptothecin with antitumor activity in solid neoplasias. Camptothecin inhibits topoisomerase I and impedes the uncoiling of the DNA double helix, thus delaying its replication and cell division. Currently, CPT-11 combined with 5-fluorouracil (5-FU) is used as a first-line treatment of advanced ... dia waguespackWebAug 11, 2015 · In all cases, dysarthria occurred during the infusion of irinotecan in the first course of treatment, persisted for several hours, and then resolved rapidly without any sequelae. Physical and neurological examinations at the onset of dysarthria revealed no other abnormalities. Imaging studies revealed no abnormal findings. diawa infinity barbel rodWebSep 12, 2024 · Hence irinotecan may cause overstimulation of hypoglossal nerve leading to dysarthria. Oxaliplatin is known to potentiate the cholinergic effects of irinotecan by causing neuronal... dia wait times nowWebMar 21, 2024 · Irinotecan (Camptosar ©, CPT-11), a topoisomerase I inhibitor, is a commonly used cytotoxic chemotherapeutic in the treatment of multiple malignancies, particularly of gastrointestinal origin.Dysarthria secondary to irinotecan has been described as a rare side effect in a few case reports with limited data to recommend appropriate … dia wall street journal advanced chartingWebBACKGROUND: Irinotecan, a topoisomerase I inhibitor, is a cytotoxic chemotherapeutic agent used to treat multiple malignancies, including those of colorectal, pancreatic, cervical, esophageal, gastric, and lung origin.Dysarthria, a state of difficult or unclear articulation of speech, has been reported as a rare side effect of irinotecan through multiple case … diawa infinity rod bagciting numerous authors harvardWebJan 18, 2012 · Irinotecan is a prodrug that requires in vivo activation by carboxylesterases to yield its active and potent metabolite, SN-38, which works in a cell cycle phase-specific (S … citing nursing central